Skip to main content
Tianjin Ringpu Bio-Technology Co.,Ltd. logo

Tianjin Ringpu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 300119 ISIN · CNE100000TV1 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,284 across all filing types
Latest filing 2025-04-25 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300119

About Tianjin Ringpu Bio-Technology Co.,Ltd.

https://www.ringpu.com

Tianjin Ringpu Bio-Technology Co.,Ltd. is a high-tech enterprise specializing in the research, development, production, and sale of animal health products. The company offers a comprehensive portfolio that includes veterinary biological products, chemical drugs, feed additives, and pet health solutions. Its product range covers vaccines for poultry and livestock, as well as various pharmaceutical formulations such as injections, powders, and oral solutions. Ringpu Bio-Technology emphasizes innovation through its dedicated R&D centers, focusing on disease prevention and treatment to support the global animal husbandry industry. The company provides integrated health management services and high-quality veterinary medicines to ensure food safety and animal welfare.

Recent filings

Filing Released Lang Actions
第五届监事会第十九次（临时）会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 19th (extraordinary) meeting of the 5th Supervisory Board of Ruipu Bio Co., Ltd. It includes details about the meeting attendance, the approval of the 2025 Q1 report, and approval of a donation related to a connected transaction. The document does not contain the actual quarterly report or detailed financial data but references the report being published on official websites and newspapers. The document is short (1156 characters) and serves as a meeting resolution announcement rather than the report itself. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and meeting resolution disclosure, not as an Interim/Quarterly Report (IR) or Annual Report (10-K).
2025-04-25 Chinese
关于独立董事任期届满离任暨补选独立董事的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the departure of an independent director due to term expiration and the subsequent election of a new independent director. It includes details about the board composition, compliance with regulatory requirements, and the qualifications of the new director candidate. There are no financial statements, earnings data, or detailed management reports. The content focuses on board/management changes, specifically about independent directors. Therefore, the document fits the category of Board/Management Information (MANG). The document length is short and it is not a report publication or certification, so it is not RPA or RNS.
2025-04-25 Chinese
北京市通商律师事务所关于瑞普生物股份有限公司2024年年度股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the 2024 Annual General Meeting (AGM) of 瑞普生物股份有限公司. It details the legality of the AGM's convening, attendance, voting procedures, and results. The document includes specific voting results on various proposals related to the company's annual reports, financial statements, profit distribution, and other corporate matters. The document is not the AGM materials themselves but a legal opinion on the AGM proceedings and voting outcomes. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting results of the AGM. The document length is about 5911 characters, which is substantive and not a mere announcement of a report publication. Therefore, the classification is DVA with high confidence.
2025-04-24 Chinese
关于回购注销部分限制性股票减少注册资本暨通知债权人的公告
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement from 瑞普生物股份有限公司 regarding the repurchase and cancellation of restricted shares, which results in a reduction of registered capital. It includes details about board and shareholder meeting approvals, the number of shares involved, and a notification to creditors about their rights. The content focuses on a capital structure change due to share repurchase and cancellation, not a financial report or earnings release. It is not a full report but an announcement of a corporate action related to share capital. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length is short (1623 characters), consistent with an announcement rather than a full report.
2025-04-24 Chinese
2024年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled as a 2024 Annual General Meeting (AGM) resolution announcement for 瑞普生物股份有限公司. It details the voting results on various proposals including the 2024 annual report, financial statements, profit distribution plan, appointment of auditors, and amendments to the company charter. The document includes detailed voting outcomes and legal opinions confirming the validity of the meeting and resolutions. It does not contain the full annual report or financial statements themselves but reports on the resolutions passed at the AGM. Therefore, this document is an official announcement of the AGM voting results, fitting the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length and content confirm it is not a brief report publication announcement or a full report but a detailed voting result announcement.
2025-04-24 Chinese
关于取得兽药产品批准文号的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the approval of a veterinary drug product by a regulatory authority (Agriculture and Rural Affairs Ministry). It contains no financial data, no mention of financial results, no regulatory filings related to financial statements, and no mention of shareholder meetings or votes. The document is an official announcement about a product approval, which is a regulatory announcement but not a financial report or management information. It is not a report publication announcement since it does not mention any report being published or attached. It fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2025-04-16 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.